Algiers, January 12, 2026 – Algerian pharmaceutical giant Saidal has signed a Memorandum of Understanding (MOU) with Swiss conglomerate Bioexpress Therapeutics, marking a significant step in bolstering international cooperation within the pharmaceutical and biotechnology sectors.
The agreement, finalized Sunday, underscores both entities’ commitment to strengthening ties and fostering innovation. According to a statement released by Saidal, the MOU establishes a strategic framework focused primarily on training and developing expertise in the field of biotechnology. This initiative aims to facilitate a gradual and structured technology transfer process, ultimately enhancing Algeria’s domestic production capabilities for biotechnological products.
This partnership is strategically designed to create an environment conducive to local manufacturing of advanced therapies. By doing so, it will strengthen national capacities and support the ongoing pursuit of health sovereignty within Algeria.
The collaboration also reinforces Saidal’s dedication to promoting innovation, nurturing local talent, and integrating cutting-edge technologies into its operations. It aligns with the company’s broader strategy of expanding its network of strategic partnerships with leading international players in the pharmaceutical and biopharmaceutical industries.
Through this agreement, Saidal reaffirms its commitment to advancing the Algerian pharmaceutical landscape and contributing to a more robust and self-reliant healthcare system. The partnership with Bioexpress Therapeutics represents a key milestone in achieving these objectives.
